Health & Medicine - Posted by Richard Mellor-Leeds on Tuesday, August 14, 2012 14:37 - 0 Comments
Drug shields heart from carbon monoxide
U. LEEDS (UK) — A common anti-angina drug may be an effective way to protect the heart against carbon monoxide poisoning.
Studies with animals show the anti-angina drug ranolazine can significantly reduce the number of deaths from arrhythmias—irregular or abnormally paced heartbeats—that have been triggered by carbon monoxide.
Published in the American Journal of Respiratory and Critical Care Medicine, the findings could have important implications for the development of a protective treatment for adults and children who have been exposed to toxic levels of the gas.
“When patients are admitted to hospital with carbon monoxide poisoning, the main problem doctors face is preventing damage to the body whilst the body slowly removes the chemical,” says Chris Peers, a professor at the University of Leeds, who led the research.
Straight from the Source
“We’ve shown that ranolazine can rapidly protect the heart and prevent the kind of cardiac events which threaten patients long after their exposure to the gas.”
Carbon monoxide poisoning causes 1.6 million deaths worldwide every year. Many people who have been exposed to the gas develop cardiac arrhythmias, which if left untreated can lead to a fatal cardiac arrest. Until now, however, the underlying biochemical mechanisms causing damage to the heart have not been fully understood, preventing the development of effective treatments.
Ranolazine, which is sold under the trade name Ranexa, was approved in 2006 in the US for the treatment of angina. The drug works by targeting a sodium channel in the heart—the same channel that can also induce irregular heartbeats.
Researchers examined the effect of ranolazine in single cardiac cells, to learn why carbon monoxide can trigger arrhythmias. They found that exposure to the gas causes a key membrane channel carrying sodium ions through the heart to stay open longer. This in turn causes calcium to build up within cells, with the combined effect altering the heart’s regular cycle.
Colleagues at the Université Montpellier and Université de Avignon in France then used ranozaline in clinical trials with rats exposed to carbon monoxide, to test its protective effects. The drug markedly reduced the chance of arrhythmia in the animals.
“Whilst the link between arrhythmias and carbon monoxide has been known for over 50 years, this is the first piece of research to explain the underlying process,” says University of Leeds’ Professor Derek Steele, who co-authored the research.
“At the molecular level, we have shown that the mechanism underlying this adverse effect of carbon monoxide is a rise in the level of nitric oxide within cells, which in turn alters the function of the sodium channel.”
The findings may also help those living in built-up areas or whose work involves daily exposure to lower levels of carbon monoxide, such as firefighters, the researchers believe. A recent and extensive epidemiological study of nine million people in the US showed a clear link between environmental carbon monoxide exposure and hospitalization due to cardiovascular complaints.
As ranolazine is a daily medication for angina, the researchers suggest it may be suitable to protect patients from the harmful effects of chronic exposure, though human clinical trials will be required to confirm this.
“The next step will be to replicate these findings in human trials. As the drug has been clinically approved, roll out of this treatment could begin soon after we have these results,” Peers says.
Hélène Wilson, research advisor at the British Heart Foundation (BHF), which co-funded the study, says: “This study is a good example of research being used to better understand the underlying causes of an abnormal heart rhythm and in this case it has uncovered the ability of an old drug to perform a new trick. Carbon monoxide poisoning is tragically common but hopefully these promising results can be replicated in people so that it saves lives in the future.”
The research is funded by the BHF, Gilead Sciences, the Wellcome Trust, and Fondation de France.
Source: University of Leeds